Carvedilol
Product Images NDC 68071-2633

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 68071-2633). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp (68071 2633 8)

Pdp (68071 2633 8)
Carvedilol 3.125 mg tablets label from NuCare Pharmaceuticals, Inc. The label states the package contains 180 oval-shaped white tablets engraved with '254' on one side. It includes dosage information, manufacturer details (Beximco Pharmaceuticals Limited, Bangladesh), and warnings to keep out of reach of children and store at controlled temperature 68-77°F. Serial numbers, lot numbers, and expiration date fields are present but not filled.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A line graph comparing the percentage mortality over 21 months between groups labeled 'Placebo' and 'Carvedilol.' The y-axis shows % Mortality, and the x-axis shows time in months. The graph demonstrates lower mortality for Carvedilol compared to Placebo, with a p-value of 0.0014 indicated.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A forest plot chart showing hazard ratios for various patient subgroups including gender, age, race, diabetic status, ischemic condition, heart rate, systolic blood pressure (SBP), and spironolactone use, with a reference line at hazard ratio 1.0. It compares outcomes across these subgroups visually using dots and horizontal lines indicating confidence intervals.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A line graph showing percent mortality over months for Carvedilol versus placebo. Two curves depict mortality rates, with Carvedilol showing lower mortality compared to placebo across 24 months. The graph includes a p-value of 0.03 indicating statistical significance between groups.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A hazard ratio forest plot chart displaying various risk factors and patient subgroups along the vertical axis. The horizontal axis represents hazard ratios ranging approximately from 0.4 to 1.3. Data points with confidence intervals are plotted for each subgroup on either side of a central reference line. Subgroups include age, sex, timing post-MI, beta-blocker use, Killip class, thrombolytic treatment, PCI status, heart failure status, medication use, and other clinical factors.*
FDA Label Image

Structural Formula (Structure)

Structural Formula (Structure)
Chemical structure of Carvedilol showing the molecular arrangement including phenyl groups and hydroxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.